1 – 10 of 10
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Five year risk assessment and treatment patterns in patients with chronic thromboembolic pulmonary hypertension
(
- Contribution to journal › Article
-
Mark
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
(
- Contribution to journal › Article
-
Mark
Plasma matrix metalloproteinase 2 is associated with severity and mortality in pulmonary arterial hypertension
(
- Contribution to journal › Article
-
Mark
ISHLT consensus statement: Perioperative management of patients with pulmonary hypertension and right heart failure undergoing surgery
(
- Contribution to journal › Article
- 2021
-
Mark
Longitudinal changes in risk status in pulmonary arterial hypertension
(
- Contribution to journal › Article
-
Mark
Plasma insulin-like growth factor binding protein 1 in pulmonary arterial hypertension
(
- Contribution to journal › Article
- 2020
-
Mark
Poor outcome of patients with pulmonary arterial hypertension with insufficient response to phosphodiesterase-5 inhibitors alone or in combination with other specific therapy : a registry-based study
(
- Contribution to journal › Article
-
Mark
Plasma adrenomedullin peptides and precursor levels in pulmonary arterial hypertension disease severity and risk stratification
(
- Contribution to journal › Article
- 2019
-
Mark
Pulmonary arterial hypertension : assessing risk to improve prognosis
(
- Contribution to journal › Article
-
Mark
Higher plasma fibroblast growth factor 23 levels are associated with a higher risk profile in pulmonary arterial hypertension
(
- Contribution to journal › Article